Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection.

The purpose of this retrospective study was to evaluate infectious complications in patients receiving mobilization chemotherapy for stem cell collection prior to autologous peripheral blood stem cell transplantation. An additional goal was to evaluate risk factors associated with the development of infectious complications. At the Medical College of Georgia BMT center, 54 patients were administered mobilization chemotherapy for the purpose of collecting stem cells between June, 1997, and May, 2002. All patients received Filgrastim in addition to chemotherapy, and 50 of 54 patients received prophylactic acyclovir, fluconazole, and ciprofloxacin until neutrophil recovery. The median duration to neutrophil recovery was 11 days. Fourteen of 54 (26%) patients developed fever/infections during the mobilization phase. One patient developed both a catheter-related infection and Clostridium difficile colitis, increasing the total number of infectious episodes to 15. Twelve patients had a documented site of infection whereas 2 patients had neutropenic fever with no identifiable source. Eight of the 15 (55%) infections were Gram-positive catheter infections. All the patients were treated successfully with antibiotics. No systemic fungal infections were identified and none of the patients died from complications related to mobilization chemotherapy. Logistic regression was applied for univariate and multivariate analysis and showed that age, sex, diagnosis, neutrophil recovery, disease status, use of salvage chemotherapy, and mobilization regimen used did not affect the infection rate. In our series of 54 patients, 14 patients developed fever/infections during mobilization. Although there is a substantial risk of infectious complications among patients who receive mobilization chemotherapy, it is not clear that prophylactic antibiotics decrease infectious complications. Because the vast majority of infections are Gram-positive catheter infections, it appears reasonable to employ Gram-positive prophylaxis. Controlled studies should be conducted to define the optimum mobilization regimens as well as the optimum combination of prophylactic antibiotics.

[1]  G. Giaccone,et al.  Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Vela-Ojeda,et al.  Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization , 2000, Bone Marrow Transplantation.

[3]  H. Akan,et al.  Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies , 2000, Bone Marrow Transplantation.

[4]  J. Clive,et al.  Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer , 2000, Bone Marrow Transplantation.

[5]  J. Wharton,et al.  High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer , 2000, Bone Marrow Transplantation.

[6]  M. Flowers,et al.  Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells , 1999, Bone Marrow Transplantation.

[7]  L. Schwartzberg,et al.  Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY , 1999, Bone Marrow Transplantation.

[8]  P. Pedrazzoli,et al.  Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen. , 1999, Haematologica.

[9]  B. Barlogie,et al.  Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Demetri,et al.  Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections , 1996, Transfusion.

[11]  G. Bucaneve,et al.  Empiric monotherapy in neutropenia: a realistic goal? , 1995, Scandinavian journal of infectious diseases. Supplementum.

[12]  W. Lee,et al.  Comparison of three mobilization regimens for peripheral blood progenitor cell rescue after high dose chemotherapy. , 1994, Progress in clinical and biological research.

[13]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.